Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Ryosuke Hino, Kenji Kabashima, Yu Kato, et al.
Cancer (2010) Vol. 116, Iss. 7, pp. 1757-1766
Open Access | Times Cited: 640

Showing 26-50 of 640 citing articles:

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 10, pp. 2773-2782
Open Access | Times Cited: 429
Immunotherapy of cancer in 2012
John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, et al.
CA A Cancer Journal for Clinicians (2012) Vol. 62, Iss. 5, pp. 309-335
Open Access | Times Cited: 417
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
Fatemeh Karimi Dermani, Pouria Samadi, Golebagh Rahmani, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 2, pp. 1313-1325
Closed Access | Times Cited: 413
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Keiichi Ota, Koichi Azuma, Akihiko Kawahara, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 17, pp. 4014-4021
Open Access | Times Cited: 412
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng, Chengwen Liu, Chunyu Xu, et al.
Cancer Research (2012) Vol. 72, Iss. 20, pp. 5209-5218
Open Access | Times Cited: 390
PD‐1 as a potential target in cancer therapy
David F. McDermott, Michael B. Atkins
Cancer Medicine (2013) Vol. 2, Iss. 5, pp. 662-673
Open Access | Times Cited: 389
PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials
Jason Madore, Ricardo E. Vilain, Alexander M. Menzies, et al.
Pigment Cell & Melanoma Research (2014) Vol. 28, Iss. 3, pp. 245-253
Closed Access | Times Cited: 373
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Xiangjiao Meng, Zhaoqin Huang, Feifei Teng, et al.
Cancer Treatment Reviews (2015) Vol. 41, Iss. 10, pp. 868-876
Closed Access | Times Cited: 371
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel, Guido Kroemer
OncoImmunology (2012) Vol. 1, Iss. 8, pp. 1223-1225
Open Access | Times Cited: 354
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Pin Wu, Dang Wu, Li‐Jun Li, et al.
PLoS ONE (2015) Vol. 10, Iss. 6, pp. e0131403-e0131403
Open Access | Times Cited: 337
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Ashley Orillion, Ayumi Hashimoto, Nur P. Damayanti, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 17, pp. 5187-5201
Open Access | Times Cited: 328
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou, Kathleen M. Mahoney, Anita Giobbie‐Hurder, et al.
Cancer Immunology Research (2017) Vol. 5, Iss. 6, pp. 480-492
Open Access | Times Cited: 322
Role of PD-1 in Regulating T-Cell Immunity
Hyun‐Tak Jin, Rafi Ahmed, Taku Okazaki
Current topics in microbiology and immunology (2010), pp. 17-37
Closed Access | Times Cited: 305
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 301
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong, Qian Sun, Xinwei Zhang
Oncotarget (2016) Vol. 8, Iss. 2, pp. 2171-2186
Open Access | Times Cited: 295
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang, Jinge Li, Ke Dong, et al.
Cellular Signalling (2014) Vol. 27, Iss. 3, pp. 443-452
Closed Access | Times Cited: 292
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper, Trần Nam Thắng, Ricardo E. Vilain, et al.
Lung Cancer (2015) Vol. 89, Iss. 2, pp. 181-188
Closed Access | Times Cited: 276
PD-L1
Anthousa Kythreotou, Abdul Siddique, Francesco Mauri, et al.
Journal of Clinical Pathology (2017) Vol. 71, Iss. 3, pp. 189-194
Open Access | Times Cited: 272
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
Joaquim Bellmunt, Stephanie A. Mullane, Lillian Werner, et al.
Annals of Oncology (2015) Vol. 26, Iss. 4, pp. 812-817
Open Access | Times Cited: 270
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum, Jacob Bledsoe, Vicente Morales‐Oyarvide, et al.
Modern Pathology (2016) Vol. 29, Iss. 9, pp. 1104-1112
Open Access | Times Cited: 265
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
Xi-Wen Bi, Hua Wang, Wen-wen Zhang, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 247
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
Blanca Homet Moreno, Antoni Ribas
British Journal of Cancer (2015) Vol. 112, Iss. 9, pp. 1421-1427
Open Access | Times Cited: 233
The intracellular signalosome of PD-L1 in cancer cells
David Escors, María Gato, Miren Zuazo, et al.
Signal Transduction and Targeted Therapy (2018) Vol. 3, Iss. 1
Open Access | Times Cited: 233
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Gaurav Bajaj, Xueyan Wang, Sachin Agrawal, et al.
CPT Pharmacometrics & Systems Pharmacology (2016) Vol. 6, Iss. 1, pp. 58-66
Open Access | Times Cited: 230
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
Dan P. Zandberg, Scott E. Strome
Oral Oncology (2014) Vol. 50, Iss. 7, pp. 627-632
Closed Access | Times Cited: 224

Scroll to top